AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

This was the stock's third consecutive day of losses.

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He has long wanted to ...

Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He’s long wanted to ...

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...

Pharma majors AbbVie and Roche were both trading lower early Tuesday after top-line results were announced from the global ...

Migraine is often dismissed as “just a bad headache.”1 Yet a report, developed and funded by biopharmaceutical company AbbVie ...

Health and Human Services Secretary Robert F. Kennedy Jr. wants to make it harder and more expensive for drug companies to advertise to patients.